Why are alpha and delta faster than wild type?

HPI and UKE researchers study origin of viral mutations

How do virus variants arise and how do they spread? This is one of the key questions of a new research project initiated jointly by researchers at the Leibniz Institute for Experimental Virology (HPI) and the University Medical Center Hamburg-Eppendorf (UKE). Particularly significant in this regard is the fact that for example the SARS-CoV-2 variants alpha and delta spread significantly faster than the original virus.

How do virus variants arise and how do they spread? (Picture: ©CDC/ Alissa Eckert, MSMI; Dan Higgins, MAMS)

An unusually high number of mutations in alpha variant B.1.1.7 has led researchers to believe that this variant may have evolved in a person with a chronic SARS-CoV-2 infection. This could have been, for example, an immunosuppressed person on antiviral therapy.

"However, the dynamics with which new variants evolve or manifest during infection and subsequent transmission events are not well understood," explains Prof. Dr. Nicole Fischer, Institute of Medical Microbiology, Virology and Hygiene at the UKE. "In the project, we are therefore addressing the origin of SARS-CoV-2 variants by systematically and comprehensively investigating the emergence and transmissibility of variants in a significant number of samples from local infection clusters."

In addition to sample collections from the UKE, particular use will be made of a SARS-CoV-2 genome surveillance platform that the HPI and the UKE have established in close collaboration with local health authorities.

Prof. Fischer: "We expect that our data will make an important contribution to understanding the emergence of complex viral variants."

The project "Emergence and Origin of SARS-CoV-2 Mutations - Intrahost SARS-CoV-2 Genetic Diversity in Immunocompetent and Immunosuppressed Patients" is funded by the German Research Foundation (DFG) within the focus grant COVID-19 for one year with 163,250 Euros.

More News

Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19.
Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19. (Photo Credit: Alissa Eckert, MSMI; Dan Higgins, MAMS)

tiakis: Treatment of COVID-19

tiakis Biotech AG announced today that a first patient has been dosed in the COMCOVID trial, a Phase Ib/II trial evaluating the Company’s key investigational ...

Read more …
The paper's main author Vasundara Srinivasan at an X-ray set-up to test protein crystals in the lab. Credit: University of Hamburg, Susanna Gevorgyan (Credit: © University of Hamburg, Susanna Gevorgyan)

Natural substances show promise against coronavirus

Three natural compounds present in foods like green tea, olive oil and red wine are promising candidates for the development of drugs against the coronavirus. ...

Read more …
The molecule has shown great potential to produce a powerful antiviral response against infections with SARS-CoV-2. (Picture: ©NicoElNino/adobe.stock.com)

Evotec: € 7.5 m grant for development of COVID-19 therapeutic

Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the ...

Read more …